Selection criteria for early breast cancer patients in the DBCG proton trial – The randomised phase III trial strategy | Zendy

Line Bjerregaard Stick | Zendy; Ebbe Laugaard Lorenzen | Zendy; E.S. Yates | Zendy; C. Anandadas | Zendy; Karen Andersen | Zendy; Cynthia Aristei | Zendy; Orla Byrne | Zendy; S. Hol | Zendy; Ingelise Jensen | Zendy; Anna M. Kirby | Zendy; Youlia Kirova | Zendy; L. Marrazzo | Zendy; A. Matías-Pérez | Zendy; Mette Marie Bruun Nielsen | Zendy; Henrik Dahl Nissen | Zendy; Sileida Oliveros | Zendy; K. Verhoeven | Zendy; Johan Vikström | Zendy; Birgitte Vrou Offersen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Selection criteria for early breast cancer patients in the DBCG proton trial – The randomised phase III trial strategy

Author(s) -

Line Bjerregaard Stick,

Ebbe Laugaard Lorenzen,

E.S. Yates,

C. Anandadas,

Karen Andersen,

Cynthia Aristei,

Orla Byrne,

S. Hol,

Ingelise Jensen,

Anna M. Kirby,

Youlia Kirova,

L. Marrazzo,

A. Matías-Pérez,

Mette Marie Bruun Nielsen,

Henrik Dahl Nissen,

Sileida Oliveros,

K. Verhoeven,

Johan Vikström,

Birgitte Vrou Offersen

Publication year - 2021

Publication title -

clinical and translational radiation oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.336

H-Index - 15

ISSN - 2405-6308

DOI - 10.1016/j.ctro.2021.01.012

Subject(s) - medicine , lung cancer , breast cancer , radiation therapy , lung , proton therapy , clinical trial , cancer , oncology

Highlights • We establish selection criteria for the randomised DBCG Proton Trial.• DBCG proton selection criteria: mean heart dose ≥ 4 Gy and/or lung V17Gy/V20Gy ≥ 37%.• ~1 in 5 patients undergoing loco-regional radiotherapy will be eligible for the trial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research